Oncology

Displaying 1 - 10 of 14


mGlu3 NAMs as Therapeutics for Chemoresistant Tumors

Targeting metabotropic glutamate receptor 3 (mGlu3) has been linked as a potential therapeutic to many neurological disorders and well as oncology through the use of dual specific mGlu2/3 Antagonists (LY341495, RO4491533, MGS0039, RO4988546).


Licensing Contact

Mike Villalobos

615.322.6751
Therapeutics
Small Molecule

Small Molecule mGlu3 NAMs as Therapeutics for CNS Disorders

The Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) has a mission to promote the translation of advances in basic science towards novel therapeutics. They have recruited faculty and staff with experience at over 10 different pharmaceutical companies to ensure a diverse set of approaches, techniques and philosophies to advancing compounds. Together they aim to de-risk drug discovery programs.


Licensing Contact

Mike Villalobos

615.322.6751
Therapeutics
Small Molecule

Diagnostics Management Team

The sheer volume of medical information available to physicians today is overwhelming. Diagnostic Management Team provides a concise, accurate method for ordering the correct diagnostic tests every time, and it returns the results in a uniform report format, easily read by the physician. This has already been launched within Vanderbilt University, with a high adoption rate amongst physicians and has already shown significant savings.


Licensing Contact

Chris Harris

615.343.4433

Inventors

Mary Zutter
Oncology

Use of Fluid Shear Stress Treatment to Enhance T Cell Activation

Researchers at Vanderbilt University have developed a technique to enhance immune cell activation by exposing cells to mechanical force while culturing. Proof-of-concept data indicate that activating immune cells with this method may improve therapeutic efficacy and reduce manufacturing expenses, making powerful CAR T cell therapies more accessible to patients in need.


Licensing Contact

Cameron Sargent

615.322.5907

Long-Lasting and Self-Sustaining Cell Therapy System

Researchers at Vanderbilt have created a novel drug delivery system using two distinct T-cell populations that interact to promote engraftment and persistence in pre-clinical models, increasing the efficacy of T-cell therapies. Furthermore, "booster" treatments can be administered months after the first dose to produce an expansion of antigen specific T cells. These advantages result in longer-term therapeutic efficacy and could reduce the number of treatments required. This system also represents a viable self-renewing platform for the delivery of biologic drugs in patients who would otherwise require frequent administration.


Licensing Contact

Cameron Sargent

615.322.5907

Primary Human Fibroblats Derived From Prostate Cancer Tissue and Normal Tissue

This research targets prostate cancer.


Licensing Contact

Karen Rufus

615.322.4295
Research Tools
Oncology
Cell Line

HCC2429 Human Lung Cancer Cell Line

This research targets HCC2429.


Licensing Contact

Karen Rufus

615.322.4295
Research Tools
Oncology
Cell Line

Anti-p19 ARF Antibody

This research targets ARG(p19).


Licensing Contact

Mike Villalobos

615.322.6751

Inventors

Stephen Hann
Research Tools
Oncology
Antibody

Mouse Anti-Kaiso Monoclonal Antibody

This research targets Kaiso.


Licensing Contact

Karen Rufus

615.322.4295

Inventors

Albert Reynolds
Research Tools
Oncology
Antibody

Rabbit Anti-Fibroblast Specific Protein 1 Polyclonal Antibody

This research targets FSP1.


Licensing Contact

Karen Rufus

615.322.4295

Inventors

Eric Neilson
Research Tools
Antibody
Assays/Screening